In this study researchers from the Loma Linda University School of Medicine show for the first time that like Survivin, the Survivin splice variants are also exosomally packaged in the breast cancer patients’ sera, mimicking the survivin splice variant pattern that we also report in breast cancer tissues. Differential expression of exosomal-Survivin, particularly Survivin-2B, may serve as a diagnostic and/or prognostic marker, a “liquid biopsy” if you will, in early breast cancer patients. Furthermore, a more thorough understanding of the role of this prominent antiapoptotic pathway could lead to the development of potential therapeutics for breast cancer patients.
Early diagnostic value of survivin and its alternative splice variants in breast cancer
Khan S, Bennit HF, Turay D, Perez M, Mirshahidi S, Yuan Y, Wall NR. (2014) Early diagnostic value of survivin and its alternative splice variants in breast cancer. BMC Cancer 14(1), 176. [article]